Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.21M

Average 2.00M

ZNTL Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $8.99M fell 15.0% year over year, ahead of the -57.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.7% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 9 analysts of $2.27M (-94.0%) for the fiscal year ending Dec 2026, a slowdown from the -56.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.99M+13.7% QoQ
Last fiscal yearDec 2025
$37.72M-56.7% YoY
LTMMar 2026
$34.97M-57.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.0%-100.0%-85.0 pp
1 year-56.7%-94.0%-37.3 pp
3-year CAGR-11.6%+11.2%+22.8 pp
5-year CAGR+47.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
37.72M USD
Year-over-year change
-56.7%
4-year CAGR
-2.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ZNTL compares with its peers on the latest reported figures

  • ZNTL's LTM Mar 2026 selling, general & admin of $34.97M is the 4th highest of the 11 companies compared; the peer median is $23.38M.
  • Its year-over-year change of -57.3% is the lowest of 11, against a peer median of -25.6%.
  • Over three fiscal years its annual growth of -11.6% compares with a peer median of -7.1%.
ZNTL Competitors Peer median
Selling, General & Admin for ZNTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$39.91M -32.7%+5.7%—
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M -27.9%-12.7%24.3%
STROSutro Biopharma, Inc.LTM Mar 2026$35.33M -27.9%-11.7%35.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$34.97M -57.3%-11.6%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$30.49M -13.9%-7.9%67.6%
TILInstil Bio, Inc.LTM Mar 2026$23.46M -41.6%-24.1%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$23.29M -40.2%-9.5%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M -23.4%-6.3%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$20.27M +8.2%-0.8%—
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M -6.9%-4.3%1736.5%
IMMXImmix Biopharma, Inc.LTM Mar 2026$15.81M +34.6%+50.4%—
Peer median (excluding ZNTL) $23.38M-25.6%-7.1%51.6%

Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00067.43M0
Cost of Revenue00000
Gross Profit00067.43M0
Gross Margin———100.0%—
Research & Development175.6M172.73M235.16M167.77M107.3M
Selling, General & Admin40.94M54.55M59.4M87.12M37.72M
Operating Expenses216.54M227.29M299.51M258.62M152.81M
Depreciation & Amortization544K1.43M1.39M1.29M739K
EBITDA(207.2M)(233.58M)(247.6M)(186.17M)(144.27M)
EBITDA Margin———-276.1%—
Operating Income(216.54M)(227.29M)(299.51M)(191.19M)(152.81M)
Operating Margin———-283.6%—
Interest Income02.26K000
Interest Expense02.58M000
Other Income / Expenses50.15M(10.3M)6.6M25.5M16.19M
Income Before Tax(166.39M)(237.58M)(292.91M)(165.69M)(136.62M)
Pre-Tax Margin———-245.7%—
Income Tax Expense(297K)(469K)(601K)177K442K
Net Income(158.73M)(236.81M)(292.19M)(165.84M)(137.06M)
Net Margin———-246.0%—
EPS (Basic)(3.72)(4.48)(4.47)(2.33)(1.91)
EPS (Diluted)(3.72)(4.48)(4.47)(2.33)(1.91)
Weighted Avg Shares42.69M52.86M65.41M71.08M71.87M
Weighted Avg Shares (Diluted)42.69M52.86M65.41M71.08M71.87M

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.